Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study-Reference-Cited by-同舟云学术

Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study

Published:2022-11-22 Issue:4 Volume:50 Page:1240-1251
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Ke Zhi-Bin,Chen Shao-Ming,Chen Jia-Yin,Chen Shao-Hao,You Qi,Sun Jiang-Bo,Xue Yu-Ting,Sun Xiong-Lin,Wu Xiao-Hui,Zheng Qing-Shui,Wei Yong,Xue Xue-Yi,Xu Ning^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-022-06047-6.pdf

Reference40 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. https://doi.org/10.3322/caac.21654.

2. Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11:308–23. https://doi.org/10.1038/nrclinonc.2014.68.

3. Pan J, Chi C, Qian H, Zhu Y, Shao X, Sha J, et al. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: a retrospective comparative study. Urol Oncol. 2019;37:991–8. https://doi.org/10.1016/j.urolonc.2019.07.009.

4. Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol. 2014;7:20. https://doi.org/10.1186/1756-8722-7-20.

5. Liu W, Yao Y, Liu X, Liu Y, Zhang GM. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2021;23:429–36. https://doi.org/10.4103/aja.aja_96_20.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment and Staging Intensification Strategies Associated with Radical Prostatectomy for High-Risk Prostate Cancer: Efficacy Evaluation and Exploration of Novel Approaches;Cancers;2024-07-05

2. Magnetic resonance imaging‐based radiomics nomogram for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high‐risk non‐metastatic prostate cancer;Cancer Medicine;2024-07

3. The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy;Urologic Oncology: Seminars and Original Investigations;2024-03

4. Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer?;Seminars in Nuclear Medicine;2024-01

5. Neoadjuvant chemohormonal therapy before radical prostatectomy in high-risk prostate cancer: a mini-review;American Journal of Clinical and Experimental Urology;2024